Research & Publications
Research & Publications
<p>RESEARCH SUPPORT</p> <p>VR5716
(CTSA UL1TR000445) Kolek (PI) 02/20/13–06/30/16 Genetically
Determined Response to Atenolol in Patients with Persistent Atrial Fibrillation</p>
<p>The goal of this study was to test the hypothesis
that polymorphisms in candidate beta-adrenergic signaling genes are associated
with response to beta-blocker therapy in subjects with persistent/permanent
atrial fibrillation. Role: PI</p> <p>American
Heart Association 13CRP16960108 Kolek (PI) 07/01/13–06/30/16
Genetically Determined Response to Atenolol in Patients with Persistent
Atrial Fibrillation</p> <p>The
goal of this study was to test the hypothesis that polymorphisms in beta-adrenergic
signaling genes and polymorphisms associated with PR interval in genome-wide
association studies are associated with response to beta-blocker therapy
in subjects with persistent/permanent atrial fibrillation. Role: PI</p>
<p>VR9644 (CTSA UL1TR000445) Kolek (PI) 07/03/14–06/30/16
A Pilot and Feasibility Study to Determine If a Common Atrial Fibrillation
Risk Locus Modulates Differential Response to Antiarrhythmic Drugs</p>
<p>The goal of this studywas to gather pilot data
for a larger study that will ultimately test the hypothesis that chromosome
4q24 variants modulate the response to antiarrhythmic drug therapy in
subjects with symptomatic atrial fibrillation. Role: PI</p>
<p><strong>PUBLICATIONS AND
PRESENTATIONS</strong></p>
<p><u>Publications</u></p>
<ol> <li> <strong>Kolek
MJ</strong>, Graves AJ, Meng Xu M, Bian A, Teixeira
PL, Shoemaker MB, Parvez B, Xu H, Heckbert SR, Ellinor PT, Benjamin EJ,
Alonso A, Denny JC, Moons KGM, Shintani AK, Harrell FE, Roden DM, Darbar
D. Evaluation of a Prediction Model for the Development of Atrial Fibrillation
in a Repository of Electronic Medical Records. JAMA Cardiol 2016; Published
online Oct. 12. </li> <li>
<strong>Kolek MJ</strong><strong>,
</strong>Patel NJ, Clair WK, Whalen SP, Rottman
JN, Kanagasundram A, Shen ST, Saavedra PJ, Estrada JC, Abraham RL, Ellis
CR. Efficacy of a Bio-Absorbable Antibacterial Envelope to Prevent Cardiac
Implantable Electronic Device Infections in High-Risk Subjects. J Cardiovasc
Electrophysiol 2015;26:1111-1116. </li> <li>
<strong>Kolek MJ</strong>,
Muehlschlegel JD, Bush WS, Parvez B, Murray KT, Stein CM, Shoemaker MB,
Blair MA, Kor KC, Roden DM, Donahue BS, Fox AA, Shernan SK, Collard CD,
Body SC, Darbar D. Genetic and clinical risk prediction model for postoperative
atrial fibrillation. Circ Arrhythm Electrophysiol 2015;8:25-31. </li>
<li> Balouch MA, <strong>Kolek
MJ</strong>, Darbar D. Improved understanding of
the pathophysiology of atrial fibrillation through the lens of discrete
pathological pathways. Glob Cardiol Sci Pract 2014;Jan:24-36. </li>
<li> <strong>Kolek MJ</strong>,
Edwards TL, Muhammad R, Balouch A, Shoemaker MB, Blair MA, Kor KC, Takahashi
A, Kubo M, Roden DM, Tanaka T, Darbar D. A Genome-Wide Association Study
to Identify Genomic Modulators of Rate Control Therapy in Patients with
Atrial Fibrillation. Am J Cardiol 2014;114:593-600. </li>
<li> <strong>Kolek MJ</strong>,
Parvez B, Muhammad R, Shoemaker MB, Blair MA, Stubblefield T, Kucera GA,
Denny JC, Roden DM, Darbar D. <a href="http://www.ncbi.nlm.nih.gov/pubmed/24161141">A
Common Variant on Chromosome 4q25 is Associated With Prolonged PR Interval
in Subjects With and Without Atrial Fibrillation.</a>
Am J Cardiol 2014;113:309-13. </li> <li>
Richardson TD, <strong>Kolek MJ</strong>,
Goyal SK, Shoemaker MB, Lewis AA, Rottman JN, Whalen SP, Ellis CR. <a
href="http://www.ncbi.nlm.nih.gov/pubmed/24028661">Comparative
outcomes of transvenous extraction of sprint fidelis and riata defibrillator
leads: a single center experience.</a> J Cardiovasc
Electrophysiol. 2014;25:36-42. </li> <li>
<strong>Kolek MJ</strong>,
Dresen WF, Wells QS, Ellis CR. Use of an Antibacterial Envelope is Associated
with Reduced Cardiac Implantable Electronic Device Infections in High-Risk
Patients. Pacing Clin Electrophysiol 2013;36:354-61. </li>
<li> Ellis CR, <strong>Kolek
MJ</strong>. Rising infection rate in cardiac electronic
device implantation; the role of the AIGISRx® antibacterial
envelope in prophylaxis. <em>Comb Prod Ther</em>.
2011;1:1–9. </li> <li>
Anderson JL, Horne BD, <strong>Kolek MJ</strong>,
Muhlestein JB, Mower CP, Park JJ, May HT, Camp NJ, Carlquist JF. Genetic
variation at the 9p21 locus predicts angiographic coronary artery disease
prevalence but not extent and has clinical utility. Am Heart J 2008;156:1155-62.
</li> <li> Rondida MT, Lappé
JM, Carlquist JF, Muhlestein JB, <strong>Kolek MJ</strong>,
Horne BD, Pearson RR, Anderson JL. Soluble CD40 ligand as a predictor
of coronary artery disease and long-term clinical outcomes in stable patients
undergoing coronary angiography. Cardiology 2008;109:196-201. </li>
<li> Horne BD, Camp NJ, Carlquist JF, Muhlestein
JB, <strong>Kolek MJ</strong>,
Nicholas ZP, Anderson JL. Multiple-polymorphism associations of seven
matrix metalloproteinase and tissue inhibitor metalloproteinase genes
with myocardial infarction and angiographic coronary artery disease. Am
Heart J 2007;154:751-8. </li> <li>
Horne BD, Camp NJ, Anderson JL, Mower CP, Clarke JL, <strong>Kolek
MJ</strong>, Carlquist JF. Multiple less common
genetic variants explain the association of the cholesteryl ester transfer
protein gene with coronary artery disease. J Am Coll Cardiol 2007;49:2053-60.
</li> <li> Carlquist JF, Horne
BD, Muhlestein JB, Lappe DL, Whiting BM, <strong>Kolek
MJ</strong>, James BC, Anderson JL. Genotypes of
the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase
complex subunit 1 conjointly determine stable warfarin dose: a prospective
study. J Thromb Thrombolysis 2006;22:191-197. </li>
<li> May HT, Horne BD, Anderson JL, Wolfert RL,
Muhlestein JB, Renlund DG, Clarke JL, <strong>Kolek
MJ</strong>, Bair TL, Pearson RR, Sudhir K, Carlquist
JF. Lipoprotein-associated phospholipase A<sub>2</sub>
independently predicts the angiographic diagnosis of coronary artery disease
and coronary death. Am Heart J 2006;152:997-1003. </li>
<li> Horne BD, Carlquist JF, Cannon-Albright LA,
Muhlestein JB, McKinney JT, <strong>Kolek MJ</strong>,
Clarke JL, Anderson JL, Camp NJ. High-resolution characterization of linkage
disequilibrium structure and selection of tagging single nucleotide polymorphisms:
application to the cholesteryl ester transfer protein gene. Ann Hum Genet
2006;70:524-34 </li> <li>Kolek
MJ, Carlquist JF, Thaneemit-Chen S, Whiting BM, Horne BD, Muhlestein JB,
Lavori P, Anderson JL. The role of a common adenosine monophosphate deaminase
(AMPD)-1 polymorphism in outcomes of ischemic and nonischemic heart failure.
J Card Fail 2005;11:677-83</li> <li>Clarke
JL, Anderson JL, Carlquist JF, Roberts RF, Horne BD, Bair TL, Kolek MJ,
Mower CP, Crane AM, Roberts WL, Muhlestein JB. Comparison of differing
C-reactive protein assay methods and their impact on cardiovascular risk
assessment. Am J Cardiol 2005;95:155-158.</li> <li>Kolek
MJ, Carlquist JF, Muhlestein JB, Whiting BM, Horne BD, Anderson JL. The
toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions
in vascular inflammation, angiographic coronary artery disease, and clinical
diabetes. Am Heart J 2004;148:1034-1040.</li> </ol>
<p><strong>Presentations</strong></p>
<ul> <li> Southeast Electrophysiology
Fellows Summit, 02/2016 <ul> <li>Venous
occlusion in a patient with RV lead failure</li>
</ul> </li> <li>
Vanderbilt Cardiovascular Research Seminar, 04/2015 <ul>
<li>Personalizing treatment for atrial fibrillation</li>
</ul> </li> <li>
American Heart Association Scientific Sessions, 11/2014 <ul>
<li>Comprehensive evaluation of QT interval during
abrupt changes in heart rate and associated neurohormonal and inflammatory
markers</li> <li>External
validation of a prediction model for the development of atrial fibrillation
in a repository of electronic medical records</li>
</ul> </li> <li>
Vanderbilt Cardiovascular Research Seminar, 01/2014 <ul>
<li>Unraveling the pathophysiology of and improving
treatment for atrial fibrillation</li> </ul>
</li> <li> American Heart
Association Scientific Sessions, 11/2013 <ul> <li>A
combined genetic and clinical risk prediction model for postoperative
atrial fibrillation</li> </ul>
</li> <li> Vanderbilt University
Cardiology Grand Rounds, 04/2013 <ul> <li>Genetic
basis of AF: converging pathways or parallel mechanisms?</li>
</ul> </li> <li>
American College of Cardiology Scientific Sessions, 04/2012 <ul>
<li>Reduced cardiac rhythm device related infections
in high-risk patients with an implanted antibacterial envelope</li>
</ul> </li> <li>
American Society of Human Genetics Scientific Meeting, 06/2005 <ul>
<li>The mannose binding lectin Arg52Cys gene coding
variant predicts angiographic coronary artery disease</li>
</ul> </li> <li>
American College of Cardiology Scientific Sessions, 04/2004 <ul>
<li>The role of a common adenosine monophosphate
deaminase (AMPD)-1 polymorphism in outcome of ischemic and non-ischemic
heart failure</li> </ul> </li>
<li> American Heart Association Scientific Sessions,
11/2003 <ul> <li>Toll-like
receptor 4 D299G polymorphism predicts lower risk of coronary artery disease
and diabetes</li> </ul> </li>
</ul>